DYMISTA 50 MCG — DIN 02432889
FLUTICASONE PROPIONATE : 50 MCG AZELASTINE HYDROCHLORIDE : 137 MCG · BGP PHARMA ULC · SPRAY, METERED DOSE · wholesale supply in Canada
Health Canada status: MARKETED
What is DYMISTA?
DYMISTA 50 MCG contains FLUTICASONE PROPIONATE : 50 MCG AZELASTINE HYDROCHLORIDE : 137 MCG. It is listed in the Health Canada Drug Product Database under DIN 02432889, held by BGP PHARMA ULC, supplied as SPRAY, METERED DOSE for NASAL administration. Health Canada currently lists it as marketed, status dated 31-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DYMISTA used for?
Symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Fluticasone, Combinations cost around the world?
Fluticasone, Combinations is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 4 | 4 | CZK███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| South Africa | single exit price | 3 | 3 | ZAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| Saudi Arabia | public | 2 | 2 | SAR███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
16 pack listings across 16 brand entries and 6 price bases, refreshed 05 Sep 2026. Ranges span every Fluticasone, Combinations pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Fluticasone, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Fluticasone, Combinations, across 3 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 1 | 1 | APO-AZELASTINE/FLUTICASONE | Sourceable in Canada |
| BGP PHARMA ULC | 1 | 1 | DYMISTA | Sourceable in Canada |
| MYLAN PHARMACEUTICALS ULC | 1 | 1 | MYLAN-AZELASTINE/FLUTICASONE | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MCG |
|---|---|
| Dosage form | SPRAY, METERED DOSE |
| Route | NASAL |
| Pack configuration (monograph) | Amber glass bottles: 25 mL (at least 120 actuations) and 10 mL (at least 28 actuations). Fitted with spray pump, applicator, and dust cap. |
| Storage | Not explicitly detailed in provided text snippet (refer to full monograph), though stability and disposal section is listed in TOC. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Fluticasone, Combinations |
|---|---|
| ATC code | R01AD58 |
| AHFS class | 04:08.00 ; 52:02.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02432889 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2432889 |
| Brand name | DYMISTA |
| Generic / active ingredient | FLUTICASONE PROPIONATE : 50 MCG AZELASTINE HYDROCHLORIDE : 137 MCG |
| Market authorization holder | BGP PHARMA ULC |
| Health Canada schedule | Prescription |
| ATC code | R01AD58 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R01AD |
| Current status | MARKETED |
| Status date | 31-Jul-2018 |
| Original market date | 2015-03-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults and children (6+): One actuation in each nostril twice daily (morning and evening). Shake gently before use. Prime before first use (6 sprays).
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to any ingredient; untreated fungal, bacterial, or tuberculosis infections of the respiratory tract.
Warnings and precautions
Risk of systemic corticosteroid effects (Cushing’s, adrenal suppression), somnolence (caution driving), local nasal effects (epistaxis, ulceration), and visual disturbances (glaucoma, cataracts).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-AZELASTINE/FLUTICASONE | 137 MCG | SPRAY, METERED DOSE | APOTEX INC | MARKETED | 02540886 |
| MYLAN-AZELASTINE/FLUTICASONE | 137 MCG | SPRAY, METERED DOSE | MYLAN PHARMACEUTICALS ULC | MARKETED | 02530341 |
2 · Same class — other molecules in ATC R01AD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Mometasone | APO-MOMETASONE · MOMETASONE · MOSASPRAY · NASAL ALLERGY AND CONGESTION RELIEF · +4 more | 9 | 6 | Yes |
| Fluticasone | 24HR NASAL ALLERGY RELIEF · ALLERGY RELIEF NASAL SPRAY · APO-FLUTICASONE · FLONASE - AEM-SUS NAS 50MCG/MD · +5 more | 9 | 4 | Yes |
| Budesonide | MYLAN-BUDESONIDE AQ · RHINOCORT AQUA · RHINOCORT AQUA 100MCG · RHINOCORT TURBUHALER 100 MCG/DOSE | 5 | 3 | Yes |
| Triamcinolone | APO-TRIAMCINOLONE AQ · NASACORT · NASACORT ALLERGY 24HR · NASACORT AQ · +1 more | 5 | 3 | Yes |
| Fluticasone, Combinations | APO-AZELASTINE/FLUTICASONE · DYMISTA · MYLAN-AZELASTINE/FLUTICASONE | 3 | 3 | Yes |
| Beclomethasone | APO-BECLOMETHASONE NASAL SPRAY · BECLOMETHASONE AQUEOUS NASAL SPRAY 50MCG/METERED DOSE · BECLOMETHASONE DIPROPIONATE NAS-SPR 50MCG/AEM · BECLOMETHASONE DIPROPIONATE NASAL INHALER · +8 more | 13 | 2 | Yes |
| Ciclesonide | APO-CICLESONIDE · OMNARIS · OMNARIS HFA | 3 | 1 | Yes |
| Fluticasone Furoate | AVAMYS | 1 | 1 | Yes |
| Mometasone, Combinations | RYALTRIS | 1 | 1 | Yes |
| Flunisolide | APO-FLUNISOLIDE NASAL SPRAY · NOVO-FLUNISOLIDE · PMS-FLUNISOLIDE · RATIO-FLUNISOLIDE · +2 more | 6 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R01AA | Ephedrine · Oxymetazoline · Phenylephrine · Xylometazoline | 76 | 18 |
| R01AX | Combinations · Ipratropium Bromide · Various | 42 | 4 |
| R01AB | Ephedrine · Naphazoline · Oxymetazoline · Phenylephrine | 12 | 1 |
| R01AC | Cromoglicic Acid · Levocabastine | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DYMISTA called?
The same molecule, Fluticasone, Combinations, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ayrux | Latin | Saudi Arabia |
| AZELASTIN/FLUTIKASON TEVA | Latin | Czechia |
| AZEMISTA™ | Latin | Bahrain |
| Dymista Nasal Spray | Latin | South Africa |
| DYMISTIN | Latin | Czechia |
| FLAZONEXAR | Latin | Czechia |
| NASAFLEX | Latin | United Arab Emirates |
| Optilast | Latin | South Africa |
| Rhinolast Nasal Spray | Latin | South Africa |
| TENERA | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.